{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:45:39Z","timestamp":1793375139950,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014554","name":"Janssen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK127138"],"award-info":[{"award-number":["R01DK127138"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21MD019394"],"award-info":[{"award-number":["R21MD019394"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI169477"],"award-info":[{"award-number":["U01AI169477"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.kint.2024.09.017","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T21:33:40Z","timestamp":1729719220000},"page":"21-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Diagnosis and management of immune checkpoint inhibitor\u2013associated nephrotoxicity: a position statement from the American Society of Onco-nephrology"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Sandra M.","family":"Herrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-2151","authenticated-orcid":false,"given":"Shruti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-6054","authenticated-orcid":false,"given":"Prakash","family":"Gudsoorkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7648-2523","authenticated-orcid":false,"given":"Nattawat","family":"Klomjit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shveta S.","family":"Motwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0989-0241","authenticated-orcid":false,"given":"Sabine","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f4nica T.","family":"Costa E Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh B.","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-8477","authenticated-orcid":false,"given":"Shuchi","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2056-1721","authenticated-orcid":false,"given":"Jaya","family":"Kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7875-090X","authenticated-orcid":false,"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8168-5811","authenticated-orcid":false,"given":"Naoka","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimda","family":"Wanchoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-5046","authenticated-orcid":false,"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2024.09.017_bib1","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib2","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/ndt\/gfaa272","article-title":"Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors","volume":"36","author":"Seethapathy","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.09.017_bib3","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.09.017_bib4","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.xkme.2020.05.015","article-title":"Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor\u2014a report of 3 cases","volume":"2","author":"Herrmann","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/j.kint.2024.09.017_bib7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.kint.2021.06.001","article-title":"Immune checkpoint inhibitor-associated electrolyte disorders: query of the Food and Drug Administration Adverse Event Reporting System","volume":"100","author":"Wanchoo","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.017_bib8","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ekir.2022.11.020","article-title":"Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors","volume":"8","author":"Farooqui","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.09.017_bib9","article-title":"Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis","volume":"11","author":"Sise","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib10","first-page":"29","article-title":"A\u00a0review of the pharmacokinetic characteristics of immune checkpoint inhibitors and their clinical impact factors","volume":"16","author":"Liu","year":"2023","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.kint.2024.09.017_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.kint.2024.09.017_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/cancers12010038","article-title":"Structure and optimization of checkpoint inhibitors","volume":"12","author":"Picardo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.kint.2024.09.017_bib13","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.09.017_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.017_bib15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2024.09.017_bib16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.017_bib17","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.017_bib18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.017_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.34067\/KID.0000152019","article-title":"Acute interstitial nephritis and checkpoint inhibitor therapy","volume":"1","author":"Manohar","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2024.09.017_bib20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.34067\/KID.0000852019","article-title":"Immune checkpoint inhibitor nephrotoxicity: update 2020","volume":"1","author":"Gupta","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2024.09.017_bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.09.017_bib22","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ekir.2020.07.011","article-title":"Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors","volume":"5","author":"Seethapathy","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.09.017_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000538274","article-title":"Association of proton pump inhibitor use and immune checkpoint inhibitor mediated acute kidney injury: a meta-analysis and a review of related outcomes","volume":"55","author":"Mohan","year":"2024","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2024.09.017_bib24","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune checkpoint inhibitors and immune-related adverse renal events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.09.017_bib25","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/ckj\/sfad109","article-title":"Immune checkpoint inhibitors and their interaction with proton pump inhibitors\u2013related interstitial nephritis","volume":"16","author":"Miao","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.09.017_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A\u00a0systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.09.017_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.09.017_bib28","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ekir.2020.05.027","article-title":"Immune check point inhibitor-associated endothelialitis","volume":"5","author":"Bobart","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.09.017_bib29","doi-asserted-by":"crossref","first-page":"E369","DOI":"10.1002\/ajh.27101","article-title":"Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: analysis from a large pharmacovigilance database","volume":"98","author":"Klomjit","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2024.09.017_bib30","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.14671121","article-title":"Electrolyte and acid-base disorders associated with cancer immunotherapy","volume":"17","author":"Uppal","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.017_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102974","article-title":"Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis","volume":"151","author":"Cantini","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.kint.2024.09.017_bib32","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/ndt\/gfaa326","article-title":"Immune checkpoint inhibitor-associated hypercalcaemia","volume":"37","author":"Izzedine","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.09.017_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100626","article-title":"Immune checkpoint inhibitor-associated sarcoidosis reaction in the kidney: case report","volume":"5","author":"Charkviani","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.kint.2024.09.017_bib34","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.017_bib35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.017_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7459268","article-title":"Hypocalcemia with immune checkpoint inhibitors: the disparity among various reports","volume":"2020","author":"Nalluru","year":"2020","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.kint.2024.09.017_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/medicina59020215","article-title":"Immune checkpoint inhibitor-induced primary hyperparathyroidism in a small-cell lung cancer patient: a case report","volume":"59","author":"Zhang","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.kint.2024.09.017_bib39","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ijc.30501","article-title":"Safety and efficacy of nivolumab in the treatment of cancers: a meta-analysis of 27 prospective clinical trials","volume":"140","author":"Tie","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106427","article-title":"Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy","volume":"83","author":"Deligiorgi","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.kint.2024.09.017_bib41","article-title":"Renal tubular acidosis an adverse effect of PD-1 inhibitor immunotherapy","volume":"2018","author":"El","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.kint.2024.09.017_bib42","article-title":"Ipilimumab- and nivolumab-induced colitis causing severe hypokalemia and QTc prolongation","volume":"2019","author":"Anson","year":"2019","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.kint.2024.09.017_bib43","article-title":"Immune checkpoint inhibitor-induced Fanconi syndrome","volume":"12","author":"Farid","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.kint.2024.09.017_bib44","article-title":"Acute diffuse renal tubulopathy in a patient with lung cancer: a case report","volume":"8","author":"Tseng","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.kint.2024.09.017_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2024.09.017_bib46","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168950","article-title":"Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis","volume":"133","author":"Moledina","year":"2023","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.09.017_bib47","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","article-title":"Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1","volume":"4","author":"Cassol","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.09.017_bib48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.kint.2018.11.009","article-title":"Interstitial nephritis in immune checkpoint inhibitor therapy","volume":"96","author":"Manohar","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.017_bib49","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","article-title":"Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis","volume":"7","author":"David","year":"2019","journal-title":"J\u00a0ImmunoTherapy Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib50","first-page":"112","article-title":"Renal injury in the setting of immune checkpoint inhibitor: report of a case of hypothyroidism and the role of positron emission tomography","volume":"4","author":"Heybeli","year":"2020","journal-title":"J\u00a0Onco-Nephrology"},{"key":"10.1016\/j.kint.2024.09.017_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100552","article-title":"Acute interstitial nephritis on positron-emission tomography-computed tomography imaging","volume":"4","author":"Miao","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.kint.2024.09.017_bib52","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00330-022-09158-8","article-title":"Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases","volume":"33","author":"Awiwi","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.kint.2024.09.017_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/JCI182275","article-title":"F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury","volume":"134","author":"Gupta","year":"2024","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.09.017_bib54","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2024.09.017_bib55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.kint.2024.09.017_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2022.1017921","article-title":"Immune checkpoint inhibitor related nephrotoxicity: advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge","volume":"2","author":"Miao","year":"2022","journal-title":"Front Nephrol"},{"key":"10.1016\/j.kint.2024.09.017_bib57","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1634\/theoncologist.2018-0764","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review","volume":"24","author":"Sise","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.kint.2024.09.017_bib58","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.3390\/cancers14215267","article-title":"Pathologic predictors of response to treatment of immune checkpoint inhibitor-induced kidney injury","volume":"14","author":"Abudayyeh","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.kint.2024.09.017_bib59","article-title":"Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI","volume":"10","author":"Gupta","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib60","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.kint.2024.09.017_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.kint.2024.09.017_bib62","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/art.40766","article-title":"Dampening of CD8+ T cell response by B cell depletion therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"N\u00e9el","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.kint.2024.09.017_bib63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40425-019-0613-1","article-title":"B\u00a0cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors","volume":"7","author":"Damsky","year":"2019","journal-title":"J\u00a0ImmunoTherapy Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib64","article-title":"Checkpoint inhibitor-related renal vasculitis and use of rituximab","volume":"8","author":"Mamlouk","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib65","article-title":"Immune checkpoint inhibitor-associated thrombotic thrombocytopenic purpura in a patient with metastatic non-small-cell lung cancer","volume":"13","author":"De Filippis","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.kint.2024.09.017_bib66","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2022.03.031","article-title":"Immune checkpoint inhibitor associated renally limited thrombotic microangiopathy \u2013 a clinical dilemma","volume":"169","author":"Badra","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib67","doi-asserted-by":"crossref","first-page":"799","DOI":"10.34067\/KID.0003962021","article-title":"Is rechallenge appropriate in patients that develop immune checkpoint inhibitor-associated AKI?: PRO","volume":"3","author":"Herrmann","year":"2022","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2024.09.017_bib68","article-title":"Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab","volume":"8","author":"Lin","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib69","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2215\/CJN.14570920","article-title":"De novo malignancies after kidney transplantation","volume":"17","author":"Al-Adra","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.017_bib70","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2024.09.017_bib71","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.017_bib72","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.kint.2024.09.017_bib73","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A\u00a0multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.017_bib74","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","volume":"20","author":"d'Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2024.09.017_bib75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and\u00a0the PD-1 pathway inhibitor nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.017_bib76","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2024.09.017_bib77","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab\u00a0+ tacrolimus\u00a0+ prednisone \u00b1 ipilimumab for kidney transplant recipients with advanced cutaneous cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2024.09.017_bib78","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2024.09.017_bib79","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2024.09.017_bib80","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41467-023-37230-4","article-title":"Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy","volume":"14","author":"Dunlap","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2024.09.017_bib81","doi-asserted-by":"crossref","first-page":"258","DOI":"10.34067\/KID.0001582022","article-title":"Onconephrology 2022: an update","volume":"4","author":"Bonilla","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2024.09.017_bib82","doi-asserted-by":"crossref","first-page":"399","DOI":"10.34067\/KID.0000422020","article-title":"Use of immune checkpoint inhibitors in end stage kidney disease patients, single center experience and review of the literature","volume":"1","author":"Hirsch","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2024.09.017_bib83","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2021.05.012","article-title":"Incidence and predictors of CKD and estimated GFR decline in patients receiving immune checkpoint inhibitors","volume":"79","author":"Chute","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.09.017_bib84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000323740","article-title":"Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality","volume":"33","author":"Na","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2024.09.017_bib85","first-page":"47","article-title":"Onconephrology: the intersections between the kidney and cancer","volume":"71","author":"Rosner","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.kint.2024.09.017_bib86","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165108","article-title":"Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis","author":"Singh","year":"2022","journal-title":"JCI Insight"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824007245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824007245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:40:23Z","timestamp":1762231223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253824007245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0085253824007245"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2024.09.017","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of immune checkpoint inhibitor\u2013associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}